Auauniversity

Panel Discussion - Infection And Urologic Implants by AUAUniversity

This educational series is supported by independent educational grants from AstraZeneca and Merck. CME Available: https://auau.auanet.org/node/31198 Based on the documented need from the 2019 AUA global needs assessment in advanced prostate cancer, the AUA has produced a new series of educational offerings for the urologic care team focused on PARP inhibitors (PARPi). The first of three in the series PARP Inhibitors: Assessing the Rapidly Evolving Treatment Landscape will address the latest developments in PARPi treatments and advanced prostate cancer care. Upon completion of this activity, participants will be able to: 1. Review recommended criteria for genetic testing of prostate cancer patients and the options for testing these men. 2. Explain importance of testing for germline pathogenic variants and their implication for utilizing novel targeted therapies such as PARP inhibitors and for cascade testing among patient family members. 3. Identify men with BRCA1/2 pathogenic variants and variants in othe

This educational series is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Pfizer, Inc. CME Available: https://auau.auanet.org/node/30861 In 2020, the Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline was released and will provide critical guidance as the management of advanced prostate cancer patients continues to expand. To increase urologists understanding of how to translate the latest scientific advances and the Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline into their clinical practice, the featured 60-minute panel discussion includes a thorough discussion of new trials and approval of agents directed at the androgen axis for treatment of mHSPC. Faculty will highlight the management of patients with advanced prostate cancer and how therapeutic options have been incorporated into evidence-based guidelines. Learning Objectives: At the conclusion of the activity, participants will be able to: 1. Identify the acti

Impacts of COVID-19 on Urology Training and Education by AUAUniversity

Crossfire In Urology - Robotic Reconstruction by AUAUniversity

At the conclusion of this activity, participants will be able to: 1. Discuss the evolving landscape of adjuvant therapy for the treatment of advanced bladder cancer and analyze the risks and benefits of the new and emerging treatment options. 2.Describe the mechanism of action and associated side effects of the new adjuvant therapy. 3. Differentiate the roles between the urologist and medical oncologist in the care of patients with bladder cancer. 4. Discuss the opportunities for the coordination of care between the urologists and medical oncologists. This educational series is supported by an independent educational grant from: Bristol Myers Squibb CME available: https://auau.auanet.org/node/30870

AUA Guidelines Case - Based Panel Stress Urinary Incontinence by AUAUniversity

Panel Discussion - Peyronie's Disease Management by AUAUniversity

Pain Management In Urologic Surgery by AUAUniversity

Bulbar Urethral Strictures 101 - A Review Of The Guidelines And Basic Management Options by AUAUniversity

Learning Objective: At the conclusion of this continuing medical education activity, the participant will be able to select different strategies for ureteroscopic renal stone surgery, determine how laser parameter selection can improve lithotripsy efficiency and identify the important safety considerations to optimize patient outcomes.

At the conclusion of this activity, participants will be able to: 1. Explain the sequencing of novel therapies and be able to identify patient progression of disease. 2. Describe a patient-specific treatment plan that optimizes the use of targeted and immunological agents for the treatment of kidney cancer. This educational series is supported by independent educational grants from: Astellas AstraZeneca Bristol Myers Squibb Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc Sanofi Genzyme UroGen Pharma, Inc. CME Available: auau.auanet.org/node/29811

At the conclusion of this activity, participants will be able to: 1. Evaluate treatment plans including the sequencing and combination of treatment options for individual patients. 2. Explain best practices in MIBC and NMIBC patient selection for various treatment options. 3. Facilitate discussions with patients and caregivers regarding their treatment options. This educational series is supported by independent educational grants from: • Astellas • AstraZeneca • Bristol Myers Squibb • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC • Merck • Pfizer, Inc • Sanofi Genzyme • UroGen Pharma, Inc. CME Available: auau.auanet.org/node/29836

Case-Based Discussion: Role of Genetic Testing in Advanced M1 CRPC & M1 CRPC Post-Docataxel Chemotherapy and End-of-Life Care Podcast (2020) Presented by Leonard Gomella, MD and Joshua Lang, MD This educational activity is supported by independent educational grants from: AbbVie Astellas AstraZeneca Bayer HealthCare Pharmaceuticals Inc. Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc. CME Available: https://auau.auanet.org/node/30124

Presented by Kelly Stratton, MD and Alicia Morgans, MD This educational activity is supported by independent educational grants from: AbbVie Astellas AstraZeneca Bayer HealthCare Pharmaceuticals Inc. Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc. CME Available: https://auau.auanet.org/node/30123

Case-Based Discussion: BCR and mHSPC and M0 CRPC Presented by Stephen Boorjian, MD and Michael Cookson, MD This educational activity is supported by independent educational grants from: AbbVie Astellas AstraZeneca Bayer HealthCare Pharmaceuticals Inc. Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc. CME Available: https://auau.auanet.org/node/30122

At the conclusion of this activity, participants will be able to: 1. Identify the role of genetic testing in men with advanced, metastatic and CRPC. 2. State the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men. 3. Describe results of genetic testing and relay this information to patients in order to facilitate shared-decision making based on the test results. 4. Explain the importance of testing for germline mutations and their implication for novel therapies such as PARP inhibitors. This educational series is supported by independent educational grants from: Astellas AstraZeneca Bristol Myers Squibb Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc Sanofi Genzyme UroGen Pharma, Inc.

At the conclusion of this activity, participants will be able to: 1. Examine racial and geographic disparities in in prostate cancer and prostate cancer care. 2. Identify important causes for disparities as well as possible remedies to address these causes. This educational series is supported by independent educational grants from: Astellas AstraZeneca Bristol Myers Squibb Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc Sanofi Genzyme UroGen Pharma, Inc.

At the conclusion of this activity, participants will be able to: 1. Identify new technologies for the treatment of urothelial carcinoma and analyze the risks and benefits of treatment. 2. Facilitate discussions with patients and caregivers regarding of urothelial carcinoma treatment options. This educational series is supported by independent educational grants from: Astellas AstraZeneca Bristol Myers Squibb Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc Sanofi Genzyme UroGen Pharma, Inc. CME Available: https://auau.auanet.org/node/29841

At the conclusion of this activity, participants will be able to: 1. Review the evidence and outcomes on the treatment of M1 HSPC, MO CRPC and M1 CRPC as outlined in the newly updated AUA Advanced, Metastatic and CRPC guidelines. 2. Improve diagnostic and therapeutic decision-making processes by illustrating the application of these guidelines in urological practice This educational series is supported by independent educational grants from: • Astellas • AstraZeneca • Bristol Myers Squibb • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC • Merck • Pfizer, Inc • Sanofi Genzyme • UroGen Pharma, Inc. CME Available: https://auau.auanet.org/node/30174